WallStreetZenWallStreetZen

NASDAQ: KMDA
Kamada Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their KMDA stock forecasts and price targets.

Forecast return on equity

Is KMDA forecast to generate an efficient return?

Company
14.84%
Industry
132.42%
Market
148.92%
KMDA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KMDA forecast to generate an efficient return on assets?

Company
10.44%
Industry
17.68%
KMDA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KMDA earnings per share forecast

What is KMDA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.50+30.84%
Avg 2 year Forecast
$0.61+60.16%
Avg 3 year Forecast
$0.69+82.53%
KMDA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

KMDA revenue forecast

What is KMDA's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$207.6M+8.2%
Avg 2 year Forecast
$230.8M+20.3%
Avg 3 year Forecast
$250.5M+30.57%
KMDA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KMDA earnings growth forecast

How is KMDA forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
25.61%
Industry
17.51%
Market
64.82%
KMDA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
KMDA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
KMDA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

KMDA revenue growth forecast

How is KMDA forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
9.4%
Industry
11.97%
Market
16.2%
KMDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KMDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KMDA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
KMDA$8.31N/AN/A
TKNO$8.99$8.00-11.01%Strong Buy
EOLS$7.14$13.00+82.07%Strong Buy
TLRY$3.61$5.00+38.50%Strong Buy
GLAS$5.49$17.00+209.65%Strong Buy
View Top Pharmaceutical Stocks

Kamada Stock Forecast FAQ

What is KMDA's earnings growth forecast for 2026-2028?

(NASDAQ: KMDA) Kamada's forecast annual earnings growth rate of 25.61% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 17.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.82%.

Kamada's earnings in 2026 is $22,252,000.On average, 6 Wall Street analysts forecast KMDA's earnings for 2026 to be $28,681,507, with the lowest KMDA earnings forecast at $26,004,874, and the highest KMDA earnings forecast at $31,496,587. On average, 5 Wall Street analysts forecast KMDA's earnings for 2027 to be $35,107,734, with the lowest KMDA earnings forecast at $29,396,814, and the highest KMDA earnings forecast at $43,004,955.

In 2028, KMDA is forecast to generate $40,011,048 in earnings, with the lowest earnings forecast at $33,919,401 and the highest earnings forecast at $45,427,769.

If you're new to stock investing, here's how to buy Kamada stock.

What is KMDA's revenue growth forecast for 2026-2028?

(NASDAQ: KMDA) Kamada's forecast annual revenue growth rate of 9.4% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.2%.

Kamada's revenue in 2026 is $191,849,000.On average, 6 Wall Street analysts forecast KMDA's revenue for 2026 to be $11,975,048,365, with the lowest KMDA revenue forecast at $11,402,802,690, and the highest KMDA revenue forecast at $12,446,343,443. On average, 5 Wall Street analysts forecast KMDA's revenue for 2027 to be $13,313,364,864, with the lowest KMDA revenue forecast at $12,679,971,969, and the highest KMDA revenue forecast at $13,832,539,368.

In 2028, KMDA is forecast to generate $14,450,357,028 in revenue, with the lowest revenue forecast at $13,652,558,874 and the highest revenue forecast at $15,153,550,051.

What is KMDA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KMDA) forecast ROA is 10.44%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.68%.

What is KMDA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KMDA) Kamada's current Earnings Per Share (EPS) is $0.38. On average, analysts forecast that KMDA's EPS will be $0.50 for 2026, with the lowest EPS forecast at $0.45, and the highest EPS forecast at $0.55. On average, analysts forecast that KMDA's EPS will be $0.61 for 2027, with the lowest EPS forecast at $0.51, and the highest EPS forecast at $0.75. In 2028, KMDA's EPS is forecast to hit $0.69 (min: $0.59, max: $0.79).

What is KMDA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KMDA) forecast ROE is 14.84%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.